GeneDx Holdings WGS Patients with third-party insurance — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about GeneDx Holdings's patients with third-party insurance — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is GeneDx Holdings's patients with third-party insurance — total revenue?
- GeneDx Holdings (WGS) reported patients with third-party insurance — total revenue of $84.92M in Q1 2026.
- How has GeneDx Holdings's patients with third-party insurance — total revenue changed year-over-year?
- GeneDx Holdings's patients with third-party insurance — total revenue increased by 24.8% year-over-year, from $68.06M to $84.92M.
- What is the long-term trend for GeneDx Holdings's patients with third-party insurance — total revenue?
- Over 4 years (2021 to 2025), GeneDx Holdings's patients with third-party insurance — total revenue has grown at a 19.5% compound annual growth rate (CAGR), from $169.33M to $345.24M.
- What does patients with third-party insurance — total revenue mean?
- This metric represents the total gross revenue generated from diagnostic testing services provided to patients covered by third-party insurance providers. It reflects the company's ability to successfully navigate reimbursement cycles, secure coverage for clinical tests, and monetize its diagnostic offerings through institutional payers. Growth in this segment indicates successful market penetration and the effectiveness of the company's billing and collection operations within the healthcare insurance ecosystem.